—
Cancer is an ever-increasing problem affecting the world’s population. Currently, there are approximately 20 million cases of cancer diagnosed annually worldwide. With a compound annual growth rate (CAGR) of 2.5%, this number is expected to approach and even exceed 30 million by 2030.
Along with the rate of cancer on the rise, the diagnostic biopsy rate is over 100 million per year globally. Just as the number of cancer cases is expected to grow, the rate of diagnostic biopsies will also increase incrementally, with the number of biopsies expected to reach 150 million in 20 years.
Cancer is a time-sensitive problem. With every delay in diagnosis more patients, clinicians, hospitals, and medical centers suffer.
The mission at Caelum Diagnostic Solutions (CDS) is to accelerate cancer care by delivering immediate diagnostic biopsy results. CDS is a seed-stage startup company developing a rapid cancer biopsy analysis tool that provides a definitive diagnosis on cancer biopsies in less than five minutes while the patient is still on the procedure table.
Tissue biopsies, followed by histopathology analysis, are currently the gold standard for the definitive diagnosis of cancer. However, they are labor intensive, take up to five business days or longer for results, are performed manually, and introduce the possibility of human error. The current time to diagnosis creates a compelling opportunity for hospitals and medical centers to conduct biopsies.
The CDS Solution:
A multiple patents-published medical device and software solution called RPIDx (Real Time Pathology and Intra Procedural Diagnostics). Caelum Diagnostics utilizes industry-standard molecular imaging to detect cancer with 94% - 99% accuracy (will need to address sens/spec later) in real-time while the patient is still in the procedure. The CDS automated system is a point-of-care tissue biopsy system utilizing FLIM and AI to analyze fresh biopsies.
This paradigm-changing method offers a streamlined biopsy for clinicians without requiring specialized training. Minimal operator intervention is required. The cost savings to hospitals, medical centers, dermatological facilities, and other sites where biopsies are performed are significant. RPIDx decreases the need for repeat biopsies, thereby reducing risk to patients and decreasing the time from diagnosis to treatment. It increases quality metrics and revenue to customers. Equally important is the need to reduce emotional trauma for the patient and families by eliminating the diagnosis wait time.
It is important to note that the RPIDx is not intended to replace traditional histopathology. While it’s normal to expect point-of-care digital pathology results to be actionable (i.e., allow for highly accelerated therapeutic decision-making), the solution will also work in tandem with routine pathology. Pathologists often struggle, sifting through copious amounts of benign tissue before cancerous tissue can be isolated. That tissue then needs to be further triaged (classified) for special studies; in the case of breast cancer, those studies include hormone receptor status, targeted receptor status, and send-out tests to genomics companies. Identifying which tissue(s) contain cancer at the point of care will help direct pathologists to the tissue of interest and inform them of the ratio of benign to malignant cells within a particular sample, thereby enabling and accelerating the triaging process. The RPIDx device, in addition to providing rapid, accurate pathology results, will lighten the heavy lift performed by pathologists as they render their final evaluation of biopsied samples.
The RPIDx represents a quantum leap in medicine, offering highly reliable biopsy results within five minutes of tissue sampling. This is a game changer for patients and providers.
For more information, please visit their website https://caelumds.com/ or email rwellner@caelumds.com
Notice: RPIDx is a registered trademark.
Contact Info:
Name: RACHEL WELLNER
Email: Send Email
Organization: CAELUM DIAGNOSTICS
Website: https://caelumds.com/
Release ID: 89140264
If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release that require attention or if there is a need for a press release takedown, we kindly request that you notify us without delay at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or guide you through the removal process. Ensuring accurate and reliable information is fundamental to our mission.
